Zobrazeno 1 - 10
of 127
pro vyhledávání: '"Ron Akehurst"'
Autor:
Linda A. Murphy, Ron Akehurst, Oriol Solà-Morales, David Cunningham, Jorge Mestre-Ferrandiz, Matthew Franklin, Gérard de Pouvourville
Publikováno v:
Value in Health. 26:43-51
Autor:
Oriol Solà-Morales, Katla Sigurðardóttir, Ron Akehurst, Linda A. Murphy, Jorge Mestre-Ferrandiz, David Cunningham, Gérard de Pouvourville
Publikováno v:
Value in Health. 26:32-42
Autor:
Gérard de Pouvourville, David Cunningham, Frank-Ulrich Fricke, Peter Lindgren, Lorenzo Mantovani, Linda A. Murphy, Oriol Solà-Morales, Jorge Mestre-Ferrandiz, Ron Akehurst
Publikováno v:
Value in Health. 26:3-10
Autor:
Linda A. Murphy, Ron Akehurst, Oriol Solà-Morales, David Cunningham, Jorge Mestre-Ferrandiz, Matthew Franklin, Gérard de Pouvourville
Publikováno v:
Value in Health. 26:20-31
Autor:
Ron Akehurst, Linda A. Murphy, Oriol Solà-Morales, David Cunningham, Jorge Mestre-Ferrandiz, Gérard de Pouvourville
Publikováno v:
Value in Health. 26:11-19
Autor:
Carla Y. Vossen, Suzette M. Matthijsse, James Horscroft, Marjolijn van Keep, A.M. Chapman, M. Schurer, Ron Akehurst
Publikováno v:
Value in Health. 25:91-103
Since 2015, Zorginstituut Nederland (ZIN) has linked disease severity ranges of 0.10 to 0.40, 0.41 to 0.70, and 0.71 to 1.00 with willingness-to-pay (WTP) reference values of €20 000, €50 000, and €80 000 per quality-adjusted life year gained,
Autor:
Sarah King, Stella Stergiopoulos, Melissa Curtis, Andrew Dillon, Ron Akehurst, Dawn Lee, Florent Guelfucci, Armel Ngami, Florence Bianic, You Li, Xiwen Ma, Siraj Ali, Vincent Miller, Sanjay Popat
Publikováno v:
Lung Cancer. 178:S36-S37
Autor:
William A. Gray, Robert I. Griffiths, Peter W. M. Elroy, Stacey L. Amorosi, Alysha M. McGovern, Michael R. Jaff, Ron Akehurst, Stefan Müller-Hülsbeck
Publikováno v:
Journal of medical economics. 25(1)
Antiproliferative therapies based on paclitaxel have been developed to extend the durability of endovascular interventions for lower-extremity atherosclerotic peripheral artery disease, resulting in improved primary vessel patency and fewer target le
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 26:1548-1557
BACKGROUND: The Institute for Clinical and Economic Review (ICER) is a prominent health technology assessment (HTA) entity in the United States that considers costs and applies economic analyses to derive price-based recommendations. ICER continues t
Autor:
Georgia Hollier-Hann, Alistair Curry, Ian Keyzor, Ron Akehurst, Brendan Davies, Kateryna Onishchenko, Fayyaz Ahmed
Publikováno v:
Journal of Medical Economics. 23:113-123
Aims: OnabotulinumtoxinA is recommended by NICE for the treatment of chronic migraine. This economic evaluation provides updated estimates of the cost-effectiveness of onabotulinumtoxinA for chroni...